HAND FOOT SYNDROME ASSOCIATED WITH DRUG SORAFENIB – UNUSUAL HISTOLOGICAL PRESENTATION

2021 ◽  
pp. 49-51
Author(s):  
Nivethitha. S ◽  
Vidhya. P ◽  
Dhanalakshmi. K ◽  
Viswanathan. P
Keyword(s):  
Skin Lesions ◽  
Hand Foot Syndrome ◽  
Cellular Carcinoma

A 60-year-old male presented with skin lesions on the limbs of both the extremities, nature of which is hyperchromatic, scaly in nature which was considered as Chronic Lichenoid Dermatoses. The patient was on treatment with Sorafenib for Hepato-Cellular Carcinoma.

scholarly journals A case report on sorafenib induced adverse reaction

2019 ◽  
Vol 5 (5) ◽  
pp. 133
Author(s):  
Irfan M. G. Khan ◽  
Sunil K. Nayak ◽  
Divyasri G. ◽  
Abhinay K. ◽  
Srideep D.
Keyword(s):  
Renal Cell Carcinoma ◽  
Adverse Reaction ◽  
Case Report ◽  
Thyroid Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Hand Foot Syndrome ◽  
Cellular Carcinoma ◽  
Carcinoma Renal Cell

<p class="abstract">Sorafenib is an oral multi-kinase inhibitor used primarily in the treatment of hepatic cellular carcinoma, renal cell carcinoma, and thyroid carcinoma. Hand-foot syndrome also is known as palmar-plantar erythrodysesthesia causes reddening, numbness, swelling of palms of hands and soles of feet. In this report, a known case of renal cell carcinoma, post right nephrectomy patient on treatment with tab sorafenib had developed the hand-foot syndrome.</p><p class="abstract"> </p>

In vivo changes in the cutaneous antioxidant status during sorafenib, sunitinib and capecitabine treatment.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21664-e21664 ◽  
Author(s):  
Sora Jung ◽  
Juergen Lademann ◽  
Jalid Sehouli ◽  
Maxim E. Darvin ◽  
Harald Fuss
Keyword(s):  
Oral Administration ◽  
Well Being ◽  
Skin Lesions ◽  
Radical Formation ◽  
Measuring System ◽  
Therapeutic Effects ◽  
Spatially Resolved ◽  
Hand Foot Syndrome ◽  
Preventive Effects

e21664 Background: A potential pathomechanism for doxorubicin-associated hand-foot syndrome (HFS) was shown based in particular on radical formation in the skin. Topically applied antioxidants (AO) have a therapeutic effect on HFS. Here, radical formation of orally administered sorafenib (Nexavar), sunitinib (Sutent) and capecitabine (Xeloda) was investigated. Methods: 26 patients were included in the study in total, including 13 patients receiving capecitabine (2-4 g/day), 7 patients receiving sunitinib (25-50 mg/day) and 6 patients sorafenib (400 mg/day). Cutaneous carotenoids serving as marker substance of the AO status of the epidermis were measured in vivo using a miniaturized measuring system based on multiple spatially resolved reflectance spectroscopy. Measurements were performed 1 day before the first oral administration and on the 10thday during the first cycle of chemotherapy including an assessment of HFS skin lesions. Results: The mean AO status in capecitabine patients showed an insignificant decrease from 4.09±0.25 to 4±0.25 and in sunitinib patients an insignificant increase from 4.32±0.36 to 4.82±0.52. The AO status in patients treated with sorafenib was shown to increase significantly from 4.77±0.32 to 5.20±0.33, p = 0.028, along with an enhanced subjective vitality and well-being. Overall 3 patients, 1 in each treatment group, developed HFS grade I during the observational period of the first cycle. Conclusions: Sorafenib-, sunitinib- and capecitabine-associated HFS might not occur due to radical formation only, but due to different underlying pathomechanisms. As an AO decay was observed previously after intravenous, but not after oral administration of chemotherapeutics, the metabolisation of these agents after oral and intravenous intake might influence HFS development. Therefore, the application of topical AO might not have preventive effects for these orally applied chemotherapeutics, as shown for capecitabine previously. As therapeutic effects of topically applied AO in case of capecitabine and sorafenib induced HFS have been reported, it seems that although the pathomechanisms are different, radical formation can occur once HFS lesions have developed.

Fine Structural Alterations in Thyroid Follicular Cells (FC) and Changes in Serum Thyroxine Produced by Feeding Polychlorinated Biphenyl (PCB) to Rats

1977 ◽  
Vol 35 ◽  
pp. 498-499
Author(s):  
W.T. Collins ◽  
Charles C. Capen ◽  
Louis Kasza
Keyword(s):  
Feed Efficiency ◽  
Polychlorinated Biphenyl ◽  
Serum Proteins ◽  
Skin Lesions ◽  
Hepatic Necrosis ◽  
Ultrastructural Changes ◽  
Lymphoid Tissues ◽  
Heat Transfer Fluids ◽  
Thyroid Follicular Cells ◽  
Peripheral Metabolism

The widespread contamination of the environment with PCB, a compound used extensively by industry in hydraulic and heat transfer fluids as well as plasticizers and solvents in adhesives and sealants, has resulted in detectable tissue levels in a large portion of the human population, domestic animals, and wildlife. Intoxication with PCB produces severe hepatic necrosis, degeneration of lymphoid tissues and kidney, skin lesions, decreased reproductive performance, reduced feed efficiency, and decreased weight gain. PCB also has been reported to reduce the binding of thyroid hormone to serum proteins and enhance the peripheral metabolism of thyroxine with increased excretion of thyroxine-glucuronide in the bile (Bastomsky, Endocrinology 95: 1150-1155, 1974).The objectives of this investigation were (1) to investigate the histopathologic, histochemical, and ultrastructural changes in thyroid FC produced by the acute (4 week) and chronic (12 week) administration of low (50 ppm) and high (500 ppm) doses of PCB to rats, (2) to correlate these alterations to changes in serum immunoreactive thyroxine concentration, and (3) to investigate the persistence of the effects of PCB on the thyroid gland.

Immunofluorescent "band" test for lupus erythematosus. II. Employing skin lesions

1970 ◽  
Vol 102 (1) ◽  
pp. 42-50 ◽  
Author(s):  
T. K. Burnham
Keyword(s):  
Lupus Erythematosus ◽  
Skin Lesions

Effects of topical mechlorethamine on skin lesions of psoriasis

1970 ◽  
Vol 102 (5) ◽  
pp. 504-506 ◽  
Author(s):  
E. Epstein
Keyword(s):  
Skin Lesions

Necrotic skin lesions associated with disseminated candidiasis

1979 ◽  
Vol 115 (2) ◽  
pp. 214-215 ◽  
Author(s):  
T. M. File
Keyword(s):  
Skin Lesions ◽  
Disseminated Candidiasis

Special Considerations In The Management Of Malignant Skin Lesions About The Eye

1993 ◽  
Vol 26 (2) ◽  
pp. 215-230
Author(s):  
Gerry F. Funk ◽  
Henry T. Hoffman ◽  
Keith D. Carter
Keyword(s):  
Skin Lesions ◽  
Malignant Skin

Don't Delay Biopsy or Diagnosis of Skin Lesions in Pregnant Patients

2006 ◽  
Vol 37 (3) ◽  
pp. 31
Author(s):  
KATE JOHNSON
Keyword(s):  
Skin Lesions

New Cancer Drug Linked to Hand-Foot Syndrome

2007 ◽  
Vol 38 (2) ◽  
pp. 1-41
Author(s):  
MIRIAM E. TUCKER
Keyword(s):  
Cancer Drug ◽  
Hand Foot Syndrome

Look for Skin Lesions in ANCA-Positive Patients

2008 ◽  
Vol 7 (2) ◽  
pp. 20
Author(s):  
BARBARA J. RUTLEDGE
Keyword(s):  
Skin Lesions
Sign in / Sign up

Export Citation Format

Share Document